Mycenax Biotech Inc. (TPEX:4726)

Mycenax Biotech Statistics

Total Valuation

Mycenax Biotech has a market cap or net worth of TWD 6.75 billion. The enterprise value is 7.51 billion.

Market Cap	6.75B
Enterprise Value	7.51B

Important Dates

The next estimated earnings date is Wednesday, November 12, 2025.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Mycenax Biotech has 207.11 million shares outstanding. The number of shares has increased by 0.42% in one year.

Current Share Class	207.11M
Shares Outstanding	207.11M
Shares Change (YoY)	+0.42%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	1.33%
Owned by Institutions (%)	0.20%
Float	117.30M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	9.28
PB Ratio	3.82
P/TBV Ratio	3.89
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-15.14
EV / Sales	10.33
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-27.55

Financial Position

The company has a current ratio of 0.84, with a Debt / Equity ratio of 0.56.

Current Ratio	0.84
Quick Ratio	0.42
Debt / Equity	0.56
Debt / EBITDA	n/a
Debt / FCF	-3.60
Interest Coverage	-16.27

Financial Efficiency

Return on equity (ROE) is -24.84% and return on invested capital (ROIC) is -9.42%.

Return on Equity (ROE)	-24.84%
Return on Assets (ROA)	-8.11%
Return on Invested Capital (ROIC)	-9.42%
Return on Capital Employed (ROCE)	-18.72%
Revenue Per Employee	1.88M
Profits Per Employee	-1.28M
Employee Count	387
Asset Turnover	0.21
Inventory Turnover	9.85

Taxes

Income Tax	-9.18M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.93% in the last 52 weeks. The beta is 0.51, so Mycenax Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.51
52-Week Price Change	-34.93%
50-Day Moving Average	36.48
200-Day Moving Average	37.75
Relative Strength Index (RSI)	28.58
Average Volume (20 Days)	246,751

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mycenax Biotech had revenue of TWD 727.40 million and -496.20 million in losses. Loss per share was -2.41.

Revenue	727.40M
Gross Profit	-225.29M
Operating Income	-444.38M
Pretax Income	-505.38M
Net Income	-496.20M
EBITDA	-199.31M
EBIT	-444.38M
Loss Per Share	-2.41

Balance Sheet

The company has 219.25 million in cash and 981.09 million in debt, giving a net cash position of -761.85 million or -3.68 per share.

Cash & Cash Equivalents	219.25M
Total Debt	981.09M
Net Cash	-761.85M
Net Cash Per Share	-3.68
Equity (Book Value)	1.77B
Book Value Per Share	8.53
Working Capital	-135.45M

Cash Flow

In the last 12 months, operating cash flow was -113.06 million and capital expenditures -159.66 million, giving a free cash flow of -272.72 million.

Operating Cash Flow	-113.06M
Capital Expenditures	-159.66M
Free Cash Flow	-272.72M
FCF Per Share	-1.32

Margins

Gross margin is -30.97%, with operating and profit margins of -61.09% and -68.22%.

Gross Margin	-30.97%
Operating Margin	-61.09%
Pretax Margin	-69.48%
Profit Margin	-68.22%
EBITDA Margin	-27.40%
EBIT Margin	-61.09%
FCF Margin	n/a

Dividends & Yields

Mycenax Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.42%
Shareholder Yield	-0.42%
Earnings Yield	-7.35%
FCF Yield	-4.04%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Mycenax Biotech has an Altman Z-Score of 3.35 and a Piotroski F-Score of 4.

Altman Z-Score	3.35
Piotroski F-Score	4